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Medications for Constipation 











Fiber/Bulk laxatives, oral: Increases stool bulk and GI motility, decreases colonic transit time. Bulk agents not helpful in managing opiate-induced constipation. Fiber contraindicated if obstructive 




 1 cup/day Gas and bloating, iron & calcium malabsorption. Up to 3 days    
Psyllium13 
 
Metamucil and others 
(OTC)  
1 dose (volume 
varies by 
formulation) up to 
tid. Mix with fluids. 
Side effects same as bran. Psyllium can cause allergic 
reactions. Do not use sugar-free formulations with 
aspartame in phenylketonuria. 
 
Granular psyllium products (Perdiem, etc) are deemed 
unsafe and ineffective due to reports of esophageal 
obstruction. Granular psyllium will be no longer be 
marketed effective October 1, 2007. 
 
 Psyllium decreases total 
& LDL cholesterol, & 
blood glucose. Give 2 h 






Methylcellulose Citrucel and others 
(OTC) 
1 dose (volume 
varies with 
formulation) up to 
tid  
Less bloating. Do not use sugar-free formulations with 
aspartame in phenylketonuria. Can swell and cause 
choking if taken dry or with inadequate fluids. 
  $30 
Calcium 
polycarbophil14 
FiberCon tabs, powder, 
and others (OTC) 
 
2 tablets daily-qid Side effects same as bran. Tablets can swell and cause 
choking if taken with inadequate fluids. 
 Has calcium 244 mg/2 
tabs. Take 1 hour before/ 
2 hours after tetracycline. 
 
$18 










given daily or in 
divided doses 
Liquid tastes bad.  Up to 3 days Efficacy is marginal 
when used alone for 
treatment; role is 
primarily prevention. Do 








240 mg daily    $6 
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Hyperosmolar agents, oral: Increased intraluminal fluid. Sorbitol & lactulose are nonabsorbed disaccharides that are metabolized by colonic bacteria into organic acids.  
 









 $43  
Lactulose Chronulac (RX) 15-30 mL daily-bid 
 





















Golytely, Colyte, (RX) 8-32 oz daily. Chill 
to improve taste. 





Golytely, etc are 
indicated for bowel 
cleansing prior to 
colonoscopy and barium 






 MiraLax15 (OTC) 
GlycoLax (RX) 
Fill bottle cap to 
white line (17 g) or 
use 1 heaping 
tablespoonful daily.  











High doses can cause diarrhea, excessive stool 
frequency, nausea, bloating, cramping, flatulence. 










Do not use in kidney 
disease unless under 
supervision of a 
physician (per OTC 
product labeling).15 
$25 
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Stimulants, oral: Alter electrolyte transport; stimulate myenteric plexus; increase motility. 
 
Bisacodyl Dulcolax, Correctol 
(OTC) 5 mg enteric-
coated tablets 
1-3 tabs daily Incontinence, hyperkalemia, abdominal cramps. 6 hours Do not take po bisacodyl 
until 1 hour after milk, 
antacids, cimetidine. 
$11.50 
Senna (sennosides A 
and B)16 
Senokot, Senokot S 
(with docusate), others 
(OTC) 
2 tabs daily up to  
4 tabs bid 
Malabsorption. ‘Cathartic colon’ with loss of 
myenteric plexus neurons and muscularis propria 
atrophy has been reported with chronic use.  
6-12 hours  $32 




   $23 




Generic (OTC) 10 oz daily or 
divided into two  
5 oz doses/day 
Drink a full glass   
(8 oz) of water with 
each dose. 
Hypermagnesemia in renal insufficiency; abdominal 
cramps; diarrhea; gas.  
 
0.5-3 hours Do not use longer than 
one week without 
consulting a physician. 
 
$60 
Magnesium hydroxide  Milk of Magnesia, 
Haley’s M-O (with 
mineral oil) (OTC; 
liquid 400 mg/tsp) 
15-30 mL daily-bid Hypermagnesemia in renal insufficiency; hyper-
phosphatemia leading to hypocalcemia; dehydration, 
abdominal cramps, incontinence. 
0.5-6 hours  $10 
 Phillips Milk of 
Magnesia tablets (OTC; 
311 mg/tab) 
 
See labeling    $7 
Sodium phosphate18 Fleet Phospho-Soda 
(OTC) 
Mix one 
tablespoonful in  
4 oz of cool water 
(per 24 hours)  
 
Drink at least an 
additional full glass 
(8 oz) of clear liquid 
after each dose. 
 
Hyperphosphatemia; hypocalcemia; hypernatremia, 
calcium phosphate precipitation; nausea; vomiting; 
diarrhea; hypotension; edema. 
Acute phosphate nephropathy has been associated with 
use. 
Elderly, individuals with kidney disease or decreased 
intravascular volume, and those using medications that 
affect renal perfusion or functions (e.g., ACE 
inhibitors, ARBs, diuretics, and possibly NSAIDs) are 
at higher risk of acute phosphate nephropathy.19 
0.5-3 hours Avoid in kidney disease 
or congestive heart 
failure. 
 
Do not exceed dose 
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Lubricant laxatives, oral 
Mineral oil (OTC) Generic (OTC) 15-45 mL/day Lipid pneumonia; malabsorption of fat-soluble 
vitamins including vitamin K in patients taking 
warfarin (theoretical concern), dehydration, 
incontinence. 
 
6-8 hours Do not take with 
docusate; take on an 
empty stomach. 
$4-8 
Suppositories: Induce evacuation by local rectal stimulation. 
 
Glycerin  Generic (OTC) 1 supp pr prn; can 
take up to daily 
 





Bisacodyl Dulcolax (OTC) 1 supp pr prn; can 
take up to daily 
 
Rectal irritation. 15-60 minutes  $36 
Enemas: Evacuation induced by distended colon; mechanical lavage. 
 
Mineral oil retention  (OTC) 100-250 mL/day pr Incontinence, mechanical trauma. 6-8 hours Avoid in neutropenia/ 
thrombocytopenia. 
$84 
Tap water  500 mL pr  Mechanical trauma. 5-15 minutes  -- 
Phosphate  Fleet (OTC) 1 unit/day pr Accumulated damage to rectal mucosa, 
hyperphosphatemia, mechanical trauma. 
5-15 minutes Do not exceed 
recommended dose. 
$36 
Soap suds  1500 mL pr  Accumulated damage to rectal mucosa, mechanical 
trauma. 
2-15 minutes  -- 
Chloride Channel Activator: Enhance chloride-rich intestinal fluid secretion without altering sodium and potassium concentrations in the serum.11 
 
 
Lubiprostone20 Amitiza (RX) 24 mcg BID Nausea, diarrhea, abdominal distension, abdominal 
pain, flatulence, vomiting, loose stools. 
Within 24 
hours 
FDA approved for 
treatment of chronic 
idiopathic constipation in 
adults. 
Avoid in patients with 
history of mechanical 
gastrointestinal 
obstruction and those 
with severe diarrhea. 
$197** 
*Cost per 1 month supply at usual dose at http://www.drugstore.com.  **Amitiza cost is AWP per McKesson. 
 
Users of this document are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical judgments based on 
the content of this document.  Our editors have researched the information with input from experts, government agencies, and national organizations.  Information and Internet 
links in this article were current as of the date of publication. 
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Treatment Options for Constipation 
 
The first step to treat most cases of 
constipation is to provide more fiber, either as a 
high-fiber diet or as supplements.1  Fiber laxatives 
increase the frequency of bowel movements by 
one to two per week.2  Fiber intake should be 
increased gradually over seven to ten days, 
starting with twice daily administration.  The 
Institute of Medicine recommends total daily fiber 
intake of 38 grams for men and 25 grams for 
women under the age of 50, and 30 grams for men 
and 21 grams for women over the age of 50.3  In 
most patients, the next step is to add an 
inexpensive saline laxative such as milk of 
magnesia.  Stimulant laxatives, lactulose, and 
polyethylene glycol are recommended if these 
interventions fail.  Sorbitol and lactulose have 
similar efficacy, but their use is limited because 
they cause gas.2  Some experts are recommending 
polyethylene glycol, now available OTC, as an 
alternative to saline laxatives such as milk of 
magnesia or before stimulants such as senna or 
bisacodyl for its benign side-effect profile.  Long-
term use of milk of magnesia has been associated 
with electrolyte imbalances and should be 
avoided in patients with renal dysfunction.  
Stimulant laxatives are more likely to cause gas 
and abdominal cramps.  Concern has been raised 
that long-term use of stimulant laxatives may 
cause neurologic damage, but this is unproven.1  
In clinical studies, plasma levels of polyethylene 
glycol in patients with end-stage renal failure is 
higher than in patients with normal renal function.  
Although still considered a safe plasma level, the 
OTC Miralax label warns against use in patients 
with kidney disease unless supervised by a 
physician.4 
For chronic constipation, psyllium, 
polyethylene glycol, lactulose, or lubiprostone 
(Amitiza) are recommended.5  Amitiza should be 
reserved for individuals with chronic constipation 
who don’t respond to or tolerate laxatives.  There 
is not enough evidence to support the use of stool 
softeners, stimulant laxatives (e.g., senna, 
bisacodyl), milk of magnesia, calcium 
polycarbophil, methylcellulose, or bran in chronic 
constipation.  Both polyethylene glycol and 
lactulose have sufficient evidence to support their 
use in chronic constipation.  Polyetheylene glycol 
appears to be modestly more effective than 
lactulose with few side effects.5  Lubiprostone is 
the only prescription product approved by the 
FDA for the treatment of chronic constipation.  
Another prescription product, Zelnorm 
(tegaserod), also approved for chronic 
constipation, was recently removed from the U.S. 
market due to serious cardiovascular adverse 
events such as angina, stroke, and heart attack.6  
The National Cancer Institute recommends a 
stimulant laxative in combination with a stool 
softener for opiate-related constipation.  Fiber 
laxatives are not indicated in this situation.7  To 
prevent constipation, a bowel program should be 
started when opiate therapy begins, especially in 
the elderly.4   
When evaluating constipation, it is important 
to consider drugs as contributors.  Prescription 
medications that can cause constipation include 
opiates, anticholinergics, tricyclic antidepressants, 
calcium channel blockers (primarily verapamil), 
chemotherapy agents (vinca alkaloids), anti-
Parkinsonian agents, sympathomimetics, 
antipsychotics, diuretics, and sedating 
antihistamines. Over-the-counter agents that may 
cause constipation include aluminum-containing 
antacids, calcium supplements, iron supplements, 
and antidiarrheal agents.1,2   
A guideline for the management of 
constipation in children is available from the 
North American Society for Pediatric 




The different constipation treatment choices 
are summarized in the previous table.  With over 
700 products on the market, it is impossible to list 
them all.  One must be careful when dealing with 
brand names for these products.  Brand extensions 
mean that a product may not contain the active 
ingredient usually associated with that brand.  For 
example, the Correctol brand name is used on 
laxatives containing bisacodyl or docusate.  The 
Fleet brand name is used on bisacodyl tablets, 
glycerin suppositories, and mineral oil or 
phosphate enemas.  The Phillips brand name is 
used on products containing milk of magnesia, 
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docusate, and calcium polycarbophil. 
The FDA recently ruled that granular 
formulations of psyllium (psyllium 
[hemicellulose], psyllium hydrophilic mucilloid, 
psyllium seed, psyllium seed [blond], psyllium 
seed husks, plantago ovata husks, and plantago 
seed) are not generally recognized as safe and 
effective and are misbranded.  The ruling was 
based on reports of esophageal obstruction related 
to the use of granular psyllium laxatives despite 
efforts promoting safe use through label warnings 
and directions.  The ruling is effective October 1, 
2007 and does not apply to psyllium containing 
laxatives in other dosage forms, including 
powders, tablets, or wafers.8 
 
Conclusion 
Approximately 4 million Americans have 
frequent constipation.9  Lifestyle modifications 
such as increasing dietary fiber and fluid intake, 
and regular physical activity are generally 
recommended before drug treatment to relieve 
temporary constipation.9  When lifestyle 
modifications fail to relieve constipation, over-
the-counter laxatives can be used.  Most over-the-
counter laxatives are recommended not to be used 
for longer than one week without consulting a 
healthcare professional.  A work up for secondary 
causes of constipation should be done in patients 
whose constipation is not relieved by over-the-
counter laxatives, and who present with 
concomitant symptoms such as nausea, vomiting, 
weight loss, rectal pain, fever, cramping, 
abdominal pain, anorexia, or family history of 
inflammatory bowel disease or colon cancer.10 
 
 
Users of this document are cautioned to use their own 
professional judgment and consult any other necessary 
or appropriate sources prior to making clinical 
judgments based on the content of this document.  Our 
editors have researched the information with input 
from experts, government agencies, and national 
organizations.  Information and Internet links in this 
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